Primary Hyperoxaluria Type 1 (PH1)
Metabolic·MeSH: Primary hyperoxaluria type 1
Prevalence
0.5 / 100K
4 drugs in development·3 companies·2 clinical trials
Drug Pipeline by Phase
Approved(2)
Phase 3(1)
| Drug | Company |
|---|---|
| dcr-phxc | Dicerna Pharmaceuticals Inc (DRNA) |
Phase 2(1)
| Drug | Company |
|---|---|
| nedosiran | Dicerna Pharmaceuticals Inc (DRNA) |
Compare drugs
Frequently asked questions
How many drugs are in development for Primary Hyperoxaluria Type 1 (PH1)?
BioSniper tracks 4 drugs in development for Primary Hyperoxaluria Type 1 (PH1) across 3 companies.
How many clinical trials target Primary Hyperoxaluria Type 1 (PH1)?
There are 2 clinical trials targeting Primary Hyperoxaluria Type 1 (PH1) tracked by BioSniper.
What is the prevalence of Primary Hyperoxaluria Type 1 (PH1)?
The estimated prevalence of Primary Hyperoxaluria Type 1 (PH1) is approximately 0.5 per 100,000 population.
Deep-dive into Primary Hyperoxaluria Type 1 (PH1)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis